Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y
RARE's Q3 loss widens and revenues miss estimates, despite year-over-year sales growth of key rare disease drugs.
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. ( RARE ) Q3 2025 Earnings Call November 4, 2025 5:00 PM EST Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis - Founder, President, CEO & Director Erik Harris - Executive VP & Chief Commercial Officer Howard Horn - Executive VP of Corporate Strategy & CFO Eric Crombez - Chief Medical Officer & Executive VP Conference Call Participants Huidong Wang - Barclays Bank PLC, Research Division Maurice Raycroft - Jefferies LLC, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Maxwell Skor - Morgan Stanley, Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Will Soghikian - Leerink Partners LLC, Research Division Joyce Chang Robbins - JPMorgan Chase & Co, Research Division Steve Scala - TD Cowen, Research Division Mehdi Goudarzi - Truist Securities, Inc., Research Division Mitchell Kapoor - H.C.
Here's What Key Metrics Tell Us About Ultragenyx (RARE) Q3 Earnings
The headline numbers for Ultragenyx (RARE) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx Pharmaceutical Inc. (RARE) Presents At Cantor Global Healthcare Conference 2025 Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Cantor Global Healthcare Conference 2025 September 4, 2025 10:55 AM EDT Company Participants Eric Crombez - Chief Medical Officer & Executive VP Howard Horn - Executive VP of Corporate Strategy & CFO Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Presentation Kristen Kluska Analyst Okay. Good morning, everybody.
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Emil D. Kakkis - Founder, President, CEO & Director Eric Crombez - Chief Medical Officer & Executive VP Erik Harris - Executive VP & Chief Commercial Officer Howard Horn - Executive VP of Corporate Strategy & CFO Joshua Higa - Director of Investor Relations & Corporate Communications Conference Call Participants Farzin Haque - Jefferies LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Jack Kilgannon Allen - Robert W.
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 Catalyst
Ultragenyx's 35% July selloff is overblown; both UX143 and UX111 programs remain on track with key catalysts ahead. UX143's Phase 3 trial continues for scientific rigor, not due to failure; pivotal data expected Q4 2025 could be transformative. UX111's FDA delay is manufacturing-related, not safety or efficacy; resubmission is planned, with approval possible in 2026.
